PHARMACY

PhRMA, D.A.R.E. partner on anti-drug abuse curriculum

BY Michael Johnsen

WASHINGTON The Pharmaceutical Research and Manufacturers of America and D.A.R.E. America jointly announced a new school curriculum Wednesday that helps counter abuse of prescription and over-the-counter drugs.

“The rise in medicine abuse, both prescription and OTC, requires action, and that is why we have worked with the manufacturers of these medicines and our own experts in developing this new curriculum,” noted Charlie Parsons, president and chief executive officer of D.A.R.E America.

The curriculum is comprised of components for students as well as presentations for parents, and was created by D.A.R.E. America, with the support and expertise of law enforcement officials; PhRMA; Abbott Laboratories; the Consumer Healthcare Products Association; the White House Office of National Drug Control Policy; the Drug Enforcement Administration; the Food and Drug Administration; the National Institute on Drug Abuse; the Substance Abuse and Mental Health Services Administrations’ Center for Substance Abuse Treatment and the Partnership for a Drug-Free America.

The new curriculum is being incorporated around the country into D.A.R.E.’s law enforcement officer-led classes during the 2007-2008 school year.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA grants Mylan tentative approval for generic Lamictal

BY Drew Buono

PITTSBURGH, Pa. Mylan Pharmaceuticals has received tentative approval from the Food and Drug Administration for a generic version of Lamictal.

Lamictal, by GlaxoSmithKline is used to treat epilepsy and bipolar I disorder. The generic version, lamotrigine, will be available in 25 mg, 100 mg, 150 mg and 200 mg tablet strengths.

The drug had sales of about $1.97 billion for the 12 months ended Sept. 30, 2007.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

NoMoreClipboard.com, ReliefInsite.com partner to offer online pain management module

BY Drew Buono

FORT WAYNE, Ind. NoMoreClipboard.com and ReliefInsite.com have teamed up to ease pain management for patients, practitioners and caregivers. The two have incorporated a free pain management module into the NoMoreClipBoard.com interface.

NoMoreClipboard.com, an online personal health record company, works with health care providers and industry groups to simplify transactions between patients, providers and payors, saving each party significant time and effort. Within NoMoreClipboard.com, patients or caregivers can store information such as allergies, medications and medical conditions in a secure environment. The patient can then choose to share their records with selected health care providers, and NoMoreClipboard.com takes care of securely transferring the record to physicians on behalf of the patient. ReliefInsite.com is a health care information technology company that provides secure online pain management services.

The ReliefInsite.com pain management module within NoMoreClipboard.com allows patients to share their daily pain diary with doctors, nurses, therapists, family members and friends. In addition, ReliefInsite.com offers dynamic, real-time graphical reports to help improve patient compliance, and assists case managers by monitoring therapy effectiveness with time-stamped records, revealing the interaction between pain levels and the patient’s personal and professional lifestyle.

“NoMoreClipboard.com allows patients to store and manage health information and share it with their health care providers, easily and seamlessly,” said Jeff Donnell, NoMoreClipboard.com vice president of marketing. “The ReliefInsite pain management module makes our personal health record even more valuable for the 50 million Americans who currently suffer from chronic pain.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?